Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
New England Journal of Medicine
2019
381
4
338-348
Association of low sexual desire with current sexual behavior, self-concept as well as comorbidities and lifestyle factors
BJU Int
2019
123 Suppl 3
39-39
Interest in, willingness-to-pay for and willingness-to-recommend genetic testing for prostate cancer among affected men after radical prostatectomy
Fam Cancer
2019
18
2
221-230
18F-RHPSMA7 POSITRON EMISSION TOMOGRAPHY FOR THE DETECTION OF BIOCHEMICAL RECURRENCE OF PROSTATE CANCER FOLLOWING RADICAL PROSTATECTOMY
J Urol
2019
201 Suppl S
4
E114-E115
ASSOCIATION OF COMMON MEDICATION WITH PROSTATE-SPECIFIC ANTIGEN LEVEL IN 45-YEAR-OLD GERMAN MEN: RESULTS OF THE PROBASE TRIAL
J Urol
2019
201 Suppl S
4
E652-E652
MORE NEGATIVE SEXUAL SELF-CONCEPT IN MEN WITH ERECTILE DYSFUNCTION, PREMATURE EJACULATION OR LOW SEXUAL DESIRE
J Sex Med
2019
16 Suppl 2
5
S66-S66
A phase II, randomized study of nivolumab (nivo) or nivo plus BMS-986205 with or without intravesical Bacillus Calmette-Guerin (BCG) in BCG-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC): CheckMate 9UT.
J Clin Oncol
2019
37 Suppl S
7
Keynote-365 cohort b: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC).
J Clin Oncol
2019
37 Suppl S
7
Keynote-365 cohort a: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).
J Clin Oncol
2019
37 Suppl S
7